Alzheimer´ s disease (AD) and related forms of dementia are increasingly affecting the aging
population throughout the world, at an alarming rate. The World Alzheimer´ s Report …

For many years Alzheimer's disease (AD) was associated with the dementia stage of the
disease, the tail end of a pathophysiological process that lasts approximately two decades …

Research progress has given detailed knowledge on the molecular pathogenesis of
Alzheimer's disease (AD), which has been translated into an ongoing development of …

Alzheimer's disease (AD) is the most common type of dementia, affecting more than 5 million
Americans, with steadily increasing mortality and incredible socio-economic burden. Not …

Alzheimer's disease (AD) is currently incurable, but there is general agreement that a
minimally invasive blood biomarker for screening in preclinical stages would be crucial for …

Alzheimer's disease (AD) is a progressive neurodegenerative disease and the single
commonest cause of dementia. Many other diseases can, however, cause dementia, and …

Highlights•Protein biomarkers in cerebrospinal fluid now define Alzheimer's disease
(AD).•New ultrasensitive techniques have enabled promising replication in blood.•This …

Biomarker testing is recommended for the accurate and timely diagnosis of Alzheimer's
disease (AD). Using illustrative case narratives we consider how cerebrospinal fluid (CSF) …

Ante-mortem diagnosis of neurodegenerative disorders based on clinical features alone is
associated with variable sensitivity and specificity, and biomarkers can potentially improve …

In 2018, there was a recent shift towards a biological definition of Alzheimer's disease (AD),
based on biomarkers measured in vivo even before the onset of clinical dementia …